Worldwide Clinical Trials Partners With Every Cure
Worldwide Clinical Trials (Worldwide) has partnered with Every Cure.
Through this new partnership, Worldwide will serve as Every Cure’s clinical trial and drug development partner. The CRO will use its clinical development and rare disease know-how to assist in identifying links between rare diseases and generic drugs on the market—all facilitated through the nonprofit’s open-source database of drug-repurposing opportunities.
Every Cure was co-founded by Dr. David Fajgenbaum, Dr. Grant Mitchell, and Tracey Sikora in 2022.
Reference
Worldwide Clinical Trials Partners with Every Cure to Accelerate Discovery of Treatments for Rare Disease Patients. (2023, May 11). Business Wire.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
